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Abstract This review is focused on the comparison
of the biological and pharmacological activities of
usnic acid enantiomers. Most of the available data
refer to (?)-usnic acid, while the left-handed isomer
has been less often significantly studied. Special
attention was paid to the experiments comparing both
(?)- and (-)-usnic acid at the same time, the results of
which indicated interesting differences, however no
tendency as to which enantiomer was more potent
could be observed. Nevertheless, more studies, espe-
cially on (-)-usnic acid, are needed to give a final
explanation for the similarities and differences
between both usnic acid enantiomers. These should
be especially directed to steric structure–activity
relationship of the enantiomers, tested under the same
experimental conditions, which may help to explain
the possible mechanisms of their actions.
Keywords Antibacterial  Chirality  Cytotoxic 
Enantiomers  Usnic acid
Introduction
Lichens are composed of different groups of microor-
ganisms. According to the traditional definition,
lichens are formed by the symbiotic co-existence of
an algal and/or a cyanobacterial and a fungal units.
However, recent reports indicate that they can be also
composed of specific basidiomycete yeasts and some
bacterial communities (Grube et al. 2009; Spribille
et al. 2016; Schneider et al. 2016). Such broad
spectrum of microorganisms makes lichens unique in
terms of chemical complexity and production of
specific compounds. One of such structurally unusual
metabolites is usnic acid (2,6-diacetyl-7,9-dihydroxy-
8,9b-dimethyl-1,3(2H,9bH)-dibenzo-furandione), a
yellow pigment, which exists in two enantiomeric
forms, depending on the position of the methyl group
at the chiral atom 9b (Fig. 1).
Enantiomers do not substantially differ in terms of
certain physical properties, like solubility, melting point
or spectroscopic characteristics (Özek et al. 2010), but
may have a different aroma or flavour (Silva et al. 2012)
and also may reveal differences in their biological and
pharmacological activity (Nguyen et al. 2006). The
current, published reviews on usnic acid have focused
mainly on the different aspects of its activity (Shrestha
and St. Clair 2013; Araújo et al. 2015; Cimmino et al.
2018), but not on its enantiospecificity. Although a lot of
experimental results describe a wide range of pharma-
cological properties of usnic acid, it is still not clear if
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there are any differences between the activities of its
enantiomers. The majority of the published data concern
(?)-usnic acid, while the information on the potential
activity of its left-handed enantiomer is scarce. More-
over, only a small number of reports refer to the activity
of (?)- and (-)-usnic acid when examined within the
same experiment. This makes the comparison even
harder. Thus, the aim of the present review is to compile
and compare the evidence available in the literature
concerning the biological and pharmacological effec-
tiveness of both usnic acid enantiomers, in order to find
potential similarities or differences in their activity.
Suggestions and challenges for future studies on lichen
chemistry and the biological activity of usnic acid are
included in this review.
Materials and methods
The following electronic English databases were
searched: Pubmed, Ovid Medline, Scopus, Web of
Science and Google Scholar, with no time limit. The
publications have been selected by using the following
keywords, combinations of ‘‘usnic acid’’: enantiomer,
enantiospecificity, antibacterial, antifungal, antibio-
film, antioxidant, cytotoxic, photoprotective, antiviral,
anitprotozoal, anti-inflammatory, analgesic, antipro-
liferative, antimitotic, antitumor, allergic, toxic and
hepatotoxic. Reference lists of all articles were also
checked for further publications. Not only were
in vitro studies with usnic acid enantiomers chosen
for this review, but also in vivo experiments on insects,
animals and humans were taken into consideration.
Although English language articles predominated in
databases, some articles in Polish, German and Czech
languages were also found.
For the purpose of this review, publications with the
stated specific rotation of usnic acid were sourced, as
well as the experiments conducted on using the (?)-
enantiomer of commercial usnic acid from Sigma-
Aldrich.
Results
Distribution and identification of usnic acid
enantiomers
As with other chiral substances that are produced in
living organisms (Finefield et al. 2012), usnic acid is
present in lichen species as one enantiomer, usually
with the predominance of one single isomer form, or
as a scalemic mixture of enantiomers. Some examples
are given in Table 1. It is noteworthy that some of the
genera tend to produce exclusively (?)- or (-)-usnic
acid, like Usnea and Alectoria, respectively, while in
others, such as Cladonia, no specific patterns of usnic
acid enantiomers biosynthesis can be identified. On
the other hand, lichen taxa in which mixtures of both
enantiomers were reported, namely Flavocetraria or
Vulpicida, belong to the cetrarioid clade of the
Parmeliaceae family. The ratio of these mixtures
was determined only in a few studies (see Table 1),
mostly by means of chiral HPLC separation (Kinoshita
et al. 1997; Smeds and Kytöviita 2010) or electronic
circular dichroism (Legouin et al. 2017). These are
useful tools for the quantitative characterization of
isomers. However, in the study by Bjerke et al. (2005)
the authors claimed that they were able to determine
the ratio of usnic acid mixture in Flavocetraria nivalis
by means of HPLC with a non-chiral column, what is
questionable. Ambiguous results relating to the
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Fig. 1 Right- (a) and left-handed (b) enantiomers of usnic acid
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content of usnic acid enantiomers can be best seen
with Cladonia stellaris, considered as one of the
richest source of (-)-usnic acid, containing up to 2%
dw of the compound (Rahman et al. 2008). The first
report on this species by Kinoshita et al. (1997)
described the presence of only one enantiomer,
namely (-)-usnic acid. In a more recent work Smeds
and Kytöviita (2010) discovered that C. stellaris
contains both usnic acid enantiomers (Table 1).
Although the predominance of the left-handed isomer
is clearly seen, the (?)-usnic acid content was
estimated to be as much as 10%. The observed
differences in the ratio of usnic acid enantiomers,
obtained by both research groups, may probably result
from the concentration of usnic acid solution used in
the analysis. However, Smeds and Kytöviita (2010)
suggest that the genetic variation of the fungal strains,
forming the lichen thallus, may also influence the
production of specific enantiomers.
Studies comparing both usnic acid enantiomers
A large number of studies on the activity of usnic acid,
in one of its enantiomeric forms, exist. Studies
comparing both enantiomers are found much less
often. There were only ca. 20 papers on this subject
published between 1948 and 2018.
Antibacterial, antifungal, antiviral activity
The results of the studies by Shibata et al. (1948) and
Bekker et al. (2015) revealed identical antibacterial
Table 1 Distribution of usnic acid enantiomers in lichens
Lichen genus Example of species References
(1)-usnic acid
Cladonia Cladonia arbuscula Einarsdottir et al. (2010)
Cladonia mitis Kinoshita et al. (1997)
Ramalina Ramalina boninensis, R. pacifica, R. roesleri Kinoshita et al. (1997)
Ramalina farinacea Tay et al. (2004)
Usnea Usnea diffracta, U. longissima, U. hirta Kinoshita et al. (1997)
Usnea steineri Lucarini et al. (2012)
Flavoparmelia Flavoparmelia caperata Kinoshita et al. (1997)
Xanthoparmelia Xanthoparmelia chlorochroa Dailey et al. (2008)
(2)-usnic acid
Cladonia Cladonia uncialis Studzińska-Sroka et al. (2015)
Cladonia stellaris Kinoshita et al. (1997)
Cladonia foliacea Koparal (2015)
Alectoria Alectoria lata Kinoshita et al. (1997)
Alectoria ochroleuca Melgarejo et al. (2008)
Mixture
Flavocetraria Flavocetraria cucculata, F. nivalis
The amount of (?)-usnic acid was one-fifth that of (-)-usnic acid
Kinoshita et al. (1997)
F. nivalis
The peak area ratio between the(-)- and (?)-usnic acid was less than1:100
Bjerke et al. (2005)
Cladonia Cladonia stellaris
0.4–10% of (?)-isomer of the total amount of usnic acid
Smeds and Kytöviita (2010)
Vulpicida Vulpicida pinastri
(?)- and (-)-usnic acid in a 35:65 ratio
Legouin et al. (2017)
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Table 2 Antibacterial activity of usnic acid enantiomers
Bacterial strain Activity References
(?)-usnic acid (-)-usnic acid
Aeromonas hydrophila – MIC 1.2 lg Yilmaz et al. (2004)
na – Tay et al. (2004)
Bacillus cereus – MIC 0.15 lg Yilmaz et al. (2004)
na – Tay et al. (2004)
– IZ 20 mm at 100 lg/ml Ivanova et al. (2004)
Bacillus subtilis – MIC 0.61 lg Yilmaz et al. (2004)
IZ 23 mm (250 lg) – Natić et al. (2004)
IZ 10 mm (60 lg) – Perry et al. (1999)
na – Correche et al. (1998)
MIC 0.036 mM – Tay et al. (2004)
– IZ 35 mm at 100 Ivanova et al. (2004)
MIC 1.2 lg/ml lg/ml Paudel et al. (2010)
IZ 40 mm at 50 mg/ml – Melgarejo et al. (2008)
Bacteroides thetaiotamicron MIC 4 lg/ml MIC 8 lg/ml Lauterwein et al. (1995)
Bacteroides vulgatus MIC 4 lg/ml MIC 8 lg/ml Lauterwein et al. (1995)
Bacteroides fragilis MIC 2 lg/ml MIC 1 lg/ml Lauterwein et al. (1995)
Bacteroides ruminicola ssp. brevis MIC 8 lg/ml MIC 16 lg/ml Lauterwein et al. (1995)
Bacteroides loeschii MIC 2 lg/ml MIC 2 lg/ml Lauterwein et al. (1995)
Clostridium perfringens MIC 4 lg/ml MIC 4 lg/ml Lauterwein et al. (1995)
Enterococcus durans MIC 37.5 lg/ml – Kukla et al. (2014)
Enterococcus faecalis IZ 23 mm at 40 mg/ml – Elo et al. (2007)
MIC 4–8 lg/ml MIC 4–16 lg/ml Lauterwein et al. (1995)
MIC 6.25 lg/ml – Tozatti et al. (2016)
MIC 9.4–18.8 lg/ml – Kukla et al. (2014)
Enterococcus faecium IZ 18–23 mm at 40 mg/ml – Elo et al. (2007)
MIC 4–16 lg/ml MIC 4–16 lg/ml Lauterwein et al. (1995)
MIC 9.4 mg/ml – Kukla et al. (2014)
Escherichia coli na – Perry et al. (1999)
IZ 5 mm at 250 lg – Natić et al. (2004)
na – Tay et al. (2004)
– IZ 0–12 mm at 100 lg/ml Ivanova et al. (2004)
na – Paudel et al. (2010)
MIC 1000 lg/ml – Schmeda-Hirschmann et al. (2008)
Helicobacter pylori MIC50 0.064 lg/ml – Safak et al. (2009)
MIC 4–8 lg/ml MIC 8–16 lg/ml Lage et al. (2018)
Klebsiella pneumoniae na – Tay et al. (2004)
– IZ 0 mm at 100 lg/ml Ivanova et al. (2004)
Listeria monocytogenes – MIC 0.31 lg Yilmaz et al. (2004)
MIC 0.018 mM – Tay et al. (2004)
IZ 20 mm at 100 lg/ml Ivanova et al. (2004)
Mycobacterium aurum MIC 32 lg/ml – Ingolfsdottir et al. (1998)
Mycobacterium avium MIC 16 lg/ml – Lucarini et al. (2012)
MIC 100 lg/ml – Ramos and da Silva (2010)
Mycobacterium chelonae MIC 25 lg/ml – Ramos and da Silva (2010)
Mycobacterium fortuitum MIC 50 lg/ml – Ramos and da Silva (2010)
Mycobacetrium kansasii MIC 8 lg/ml – Lucarini et al. (2012)
MIC 12.5 lg/ml – Ramos and da Silva (2010)
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Table 2 continued
Bacterial strain Activity References
(?)-usnic acid (-)-usnic acid
Mycobacterium smegmatum – IZ 0 mm at 100 lg/ml Ivanova et al. (2004)
Mycobacterium tuberculosis 1:160000* 1:160000* Shibata et al. (1948)
MIC 8 lg/ml – Lucarini et al. (2012)
MIC 1.56–12.5 lg/ml – Ramos and da Silva (2010)
IZ 8 mm at 75 nmol/disc IZ 8 mm at 75 nmol/disc Bekker et al. (2015)
Propionibacterium acnes MIC 2 lg/ml MIC 2 lg/ml Lauterwein et al. (1995)
Proteus vulgaris – MIC 0.15 lg Yilmaz et al. (2004)
MIC 0.036 mM – Tay et al. (2004)
Pseudomonas aeruginosa na – Perry et al. (1999)
IZ 5 mm at 250 lg – Natić et al. (2004)
na – Tay et al. (2004)
– IZ 12–18 mm at 100 lg/ml Ivanova et al. (2004)
na – Paudel et al. (2010)
MIC 750 lg/ml – Schmeda-Hirschmann et al. (2008)
IZ 18 mm at 50 mg/ml – Melgarejo et al. (2008)
Pseudomonas syringae na – Tay et al. (2004)
Salmonella enteritidis MIC 750 lg/ml – Schmeda-Hirschmann et al. (2008)
Salmonella typhimurium na – Tay et al. (2004)
Ivanova et al. (2004)
Shigella flexneri IZ 30 mm at 50 mg/ml – Melgarejo et al. (2008)
Staphylococcus aureus – MIC 2.4 lg Yilmaz et al. (2004)
MIC 6.06 lg/ml – Correche et al. (1998)
MIC 0.15 mM – Tay et al. (2004)
IZ 13–16 mm at 40 mg/ml – Elo et al. (2007)
MIC 2–16 lg/ml
1:160 000*
MIC 2–16 lg/ml
1:320,000*
Lauterwein et al. (1995)
– MIC 2.5 lg/ml Shibata et al. (1948)
– MIC 25 lg/ml Studzińska-Sroka et al. (2015)
MIC 50 lg/ml – Gupta et al. (2012)
– IZ 25–40 mm at 100 lg/ml Tozatti et al. (2016)
Ivanova et al. (2004)
MIC 5.6 lg/ml –
MIC 100–750 lg/ml – Paudel et al. (2010)
MIC 64 lg/ml Schmeda-Hirschmann et al. (2008)
IZ 20 mm at 50 mg/ml Pompilio et al. (2016)
Melgarejo et al. (2008)
Staphylococcus epidermidis MIC 6.25 lg/ml – Tozatti et al. (2016)
– IZ 16 mm at 100 lg/ml Ivanova et al. (2004)
Staphylococcus haemolyticus MIC 25 lg/ml – Tozatti et al. (2016)
Streptococcus faecalis – MIC 0.15 lg Yilmaz et al. (2004)
MIC 0.073 mM – Tay et al. (2004)
Streptococcus pyogenes IZ 16–18 mm at 150–200 lg/ml – Nithyanand et al. (2015)
– IZ 15 mm at 100 lg/ml Ivanova et al. (2004)
Yersinia enterocolitica MIC 0.018 mM – Tay et al. (2004)
– IZ 16 mm at 100 lg/ml Ivanova et al. (2004)
Yersinia pseudotuberculosis – IZ 0 mm at 100 lg/ml Ivanova et al. (2004)
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activity for both enantiomers against Mycobacterium
tuberculosis, while the effect against Staphylococcus
aureus was higher in the case of (-)-usnic acid.
Lauterwein et al. (1995) reported that both enan-
tiomers had the same antibacterial activity against five
out of ten tested bacteria strains (see Table 2). Data on
another four bacterial strains showed the predominant
effect of (?)-usnic acid. Only in the case of Bacteri-
oides fragilis did the left-handed enantiomer show
more activity. In a recent study of Lage et al. (2018),
both usnic acid enantiomers were effective inhibitors
of six clinical isolates and one reference strain of
Helicobacter pylori. It is interesting to note that (?)-
usnic acid was at least two-times more active in
comparison to its (-)-enantiomer, with the exception
of the reference strain and one clinical isolate, where
the MIC values were equal for both enantiomers.
Moreover, (?)- and (-)-usnic acid inhibited the
activity of urease, an enzyme produced by H. pylori
to colonize the stomach, by 45.3 and 33.1%,
respectively.
The only work comparing the antifungal activity of
both compounds was the study of Halama and Van
Haluwin (2004), in which no activity was shown by
usnic acid enantiomers against the plant pathogenic
fungal strains: Phytophthora infestans, Pythium ulti-
mum and Ustilago maydis.
Antiviral potency of both usnic acid enantiomers
was compared in two subsequent experiments in
which (-)-usnic acid not only revealed significantly
stronger in vitro activity against A(H1N1)pdm09
influenza virus in comparison to its (?)-enantiomer,
with ED50 values 14.5 and 51.7 lM (Sokolov et al.
2012), respectively, but also inhibited replication of
the virus in MDCK cells more effectively than (?)-
usnic acid (Shtro et al. 2014). On the contrary, (?)-
usnic acid appeared to be a more potent inhibitor
(ED50 1.0 mg/ml) of Epstein–Barr virus activation,
induced by a tumor promoter teleocidin B-4, in
comparison to the left-handed enantiomer, with ED50
1.0 and 5.0 lM, respectively (Yamamoto et al. 1995).
Antiprotozoal and insecticidal activity
In the study by Verotta et al. (2007), no significant
differences were observed between the antiplasmodial
activity of the tested enantiomers against Plasmodium
falciparum, with IC50 values 15.3 and 16.1 lM, for
(?)- and (-)-usnic acid, respectively. The
antimalarial potential of both compounds was low,
in comparison to chloroquine (IC50 0.089 lM).
Cetin et al. (2008) examined the insecticidal
activity of usnic acid enantiomers against the larvae
of the house mosquito Culex pipiens. After 24 h
exposure to both compounds, strong and dose-depen-
dent larvicidal activity was observed, with LC50
values 0.9 and 0.8 ppm for right- and left-handed
usnic acid, respectively. In the study of Emmerich
et al. (1993), the toxicity and antifeedant activity of
(?)- and (-)-usnic acids were examined against the
larvae of Spodoptera littoralis, an herbivorous
insect. Although both enantiomers provoked strong
mortality and growth retardation of the larvae, as a
consequence of their antifeedant properties, the left-
handed enantiomer was significantly more active in
comparison to its right-handed form, with LD50 value
8.6 and 90.8 lmol/g dw, respectively. The results of
the study are noteworthy, as this is the only example of
such vast, almost tenfold difference in the activity of
both enantiomers.
Phytotoxic activity
The results presented by Romagni et al. (2000)
indicated significant differences between both usnic
acid enantiomers in their phytotoxic activity. Left-
handed usnic acid caused a dose-dependent bleaching
of cotyledonary tissues of Lactuca sativa and Allium
cepa produced in in vitro cultures. This was a result of
the decrease in the amounts of chlorophyll and
carotenoids. No activity was observed for (?)-usnic
acid. Moreover, (-)-usnic acid inhibited the activity
of protoporphyrinogen oxidase and also irreversibly
inhibited 4-hydroxyphenylpyruvate dioxygenase, the
enzymes involved in chlorophyll and carotenoids
conversions.
Cytotoxic activity
Only a few authors compared both enantiomers using
the same experimental conditions (Koparal et al. 2006;
Bazin et al. 2008; Einarsdottir et al. 2010; Prokopiev
et al. 2017). The results are summarized in Table 4.
The influence of both compounds on a variety of
murine and human cancer cell lines was presented by
Bazin et al. (2008). The results indicate that (?)-usnic
acid was more active against murine L1210 and
human K-562 leukemias. It was also active against
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human prostate DU145 and breast MCF7cancer, while
(-)-usnic acid was stronger only in the case of murine
lung cancer 3LL. It is noteworthy that both enan-
tiomers revealed comparable cytotoxicity against
human glioblastoma U251. Similarly, the study by
Koparal et al. (2006), showed (?)-usnic acid to be
more active, against both tested cell lines, namely
murine fibroblasts V79 and human lung A549 cancer
cells, than its right-handed isomer. However the
results of Einarsdottir et al. (2010) showed no
differences in cytotoxicity when both enantiomers
were tested against human breast T 47-D and pancre-
atic Capan-2 cancer cells. In addition, the study of
Prokopiev et al. (2017), suggests more pronounced
cytotoxic effect of (?)-usnic acid on human blood
lymphocytes.
Genotoxic activity
Prokopiev et al. (2018) indicated significant differ-
ences between genotoxic activities of both usnic acid
isomers on human peripheral-blood lymphocytes. The
results were more profound at higher tested concen-
trations of 0.15 and 0.30 mM. The effect of (-)-usnic
acid was two times higher than its (?)-enantiomer,
and was accompanied by the atypical DNA comets,
formed with much higher frequency for the former
isomer. It is noteworthy that the same authors
described antigenotoxic and progenotoxic properties
of both enantiomers depending on the concentration
used. These compounds reduced DNA damage and the
number of atypical DNA comets, provoked by the use
of genotoxicants dioxidine and methyl methanesul-
fonate, in blood lymphocytes at concentrations up to
1 lM. However, at the dose of 100 lM both usnic acid
isomers enhanced the genotoxicity of the toxins and no
significant differences between the impact of the
enantiomers was observed. Similar investigations by
Koparal et al. (2006) indicated that neither of the usnic
acid enantiomers showed genotoxicity in human
lymphocytes in the cytokinesis-blocked micronucleus
assay.
Allergic potency
An early observation by Mitchell and Shibata (1969)
showed the differences in immunologic response
between both usnic acid isomers. Seven forest work-
ers, developed contact allergies after working in the
forested areas for a period of time. They were
subjected to patch tests and in six cases, the response
following application of (?)-usnic acid (0.1%) was
positive, while (-)-usnic acid, at much higher con-
centration (5%) did not cause any reaction. In the case
of racemic usnic acid (1%) contact dermatitis was
observed in six of the seven tested workers. The
authors suggest that the allergic potential may depend
on the presence of a COCH group at position 8 and a
CH group at position 6, as in (?)-usnic acid. More-
over, in their previous work, the authors stated that
application of usnic acid (up to 50%) to healthy
individuals, without previous contact dermatitis,
caused no primary skin irritation (Mitchell and
Armitage 1965). Opposite results were described by
Salo et al. (1981), in a study of lichen pickers, who
reacted to both usnic acid enantiomers. This observa-
tion was in agreement with the study of Hausen et al.
(1993), on the sensitizing potency of both usnic acid
forms on the guinea pigs by a modified FCA (Freund’s
complete adjuvant). Although generally weak, in
comparison to standard sensitizers, (–)-usnic acid
was at least two times stronger than (?)-usnic acid.
Activity reported solely for (?)-usnic acid
Antibacterial activity and antibiofilm properties
The antibacterial activity of (?)-usnic acid, presented
in Table 2, ranged from significantly high to rather
weak, with MIC values from 2 to 1000 lg/mL. It is
noteworthy that the antibacterial effect described by
various authors for the same bacterial strain is
sometimes as much as tenfold stronger. This can be
seen with Staphylococcus aureus.
At present, only few studies suggest a possible
mechanism for the antimicrobial activity of (?)-usnic
acid. In one study, using Staphylococcus aureus
MRSA strains, the authors suggest that this compound
exerts its antibacterial activity by damaging the
bacterial membrane. Further studies in animals (Gupta
et al. 2012) showed a significant decrease in microbial
load at doses of 1–5 mg/kg. Another study showed
that (?)-usnic acid caused a strong inhibition of RNA
and DNA synthesis in Bacillus subtilis and S. aureus,
but not in Escherichia coli, with only a slight effect in
Vibrio harveyi. Moreover, this compound also influ-
enced the translation process and inhibited the protein
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synthesis in B. subtilis and S. aureus (Maciąg-
Dorszyńska et al. 2014).
Several studies indicate that (?)-usnic acid may
inhibit the formation of both Gram-positive and Gram-
negative bacteria biofilm. In one of the study (?)-
usnic acid inhibited the formation of biofilm in four
serotypes of Streptococcus pyogenes, responsible for
pharyngitis. Not only was the biofilm biomass
reduced, but there was also the decrease in protein
and fatty acid components of the biofilm forming cells
(Nithyanand et al. 2015).
Some practical aspects for the antibiofilm activity
of (?)-usnic acid were described by Francolini et al.
(2004). They showed that addition of (?)-usnic acid to
polymeric materials in small medical devices pre-
vented bacterial attachment and biofilm formation and
significantly inhibited the growth of Staphylococcus
aureus but not Pseudomonas aeruginosa, when com-
pared to the control.
A similar effect was described by Kim et al. (2011),
in which (?)-usnic acid added to polymethyl-
methacrylate (PMMA)-based bone cement signifi-
cantly decreased methicillin-resistant Staphylococcus
aureus biofilm formation. Stan et al. (2016), devel-
oped a nanostructured bioactive surface, consisting of
zinc oxide, sodium stearate and (?)-usnic acid. The
addition of the latter significantly inhibited the adher-
ence and biofilm formation of Salmonella enterica, a
known food pathogen, when compared to a surface
without (?)-usnic acid.
Grumezescu et al. (2011) reported that (?)-usnic
acid, formulated in nano or microparticles, signifi-
cantly inhibited Staphylococcus aureus biofilm for-
mation on coverslips coated with a tested nanofluid.
Few years later the authors discovered that (?)-usnic
acid, loaded into magnetic polylactic-co-glycolic
acid-polyvinyl alcohol (PLGA-PVA) microspheres,
inhibited not only the initial attachment of S. aureus to
the coated surface, but also the development of mature
biofilms (Grumezescu et al. 2014). Similar studies by
Martinelli et al. (2014) revealed that (?)-usnic acid-
loaded into carboxylated poly(L-lactide) microparti-
cles was able to inhibit 24-h Staphylococcus epider-
midis biofilm, with results that were more profound
than the use of (?)-usnic acid alone.
A possible mechanism for the antibiofilm activity
of (?)-usnic acid against methicillin-resistant Staphy-
lococcus aureus was recently published by Pompilio
et al. (2016), who state that the effect may be a
consequence of the impaired adhesion to the host
matrix binding proteins, but also may be due to the
decrease in lipase and thermonuclease expression.
Salta et al. (2013) described the effect of (?)-usnic
acid on biofilm formation of two Gram-negative
marine bacteria, Cobetia marina and Marinobacter
hydrocarbonoclasticus, which cause biofouling and
damage to the underwater hull of the ships. The tested
compound significantly inhibited the attachment of M.
hydrocarbonoclasticus at the highest tested concen-
tration of 40 ppm. In the concentration range from 0.1
to 20 ppm the adhesion remained unaffected. For C.
marina, an enhancement in adhesion, rather than
inhibitory effect, was observed for all tested
concentrations.
Antifungal activity and antibiofilm properties
Antifungal activity of (?)-usnic acid is shown in
Table 3. The compound appears to have rather a weak
antifungal effect on a number of pathogenic and non-
pathogenic fungi and yeasts, with MIC values fre-
quently above 100 lg/mL.
Some studies also report the influence of (?)-usnic
acid on the fungal biofilm of different Candida strains.
This compound not only significantly inhibited C.
albicans biofilm formation, by reducing viability of
the cells in the already existing biofilm and preventing
further adhesion, but also reduced the thickness of
matured biofilms (Nithyanand et al. 2015). In another
study (?)-usnic acid at the concentration of 4 lg/mL
caused significant biofilm inhibition: 71.08% for
azole-resistant and 87.84% for azole-sensitive C.
albicans strains (Peralta et al. 2017). Pires et al.
(2012) examined the antibiofilm effect of (?)-usnic
acid on two Candida strains, C. orthopsilosis and C.
parapsilosis. Although the lowest concentration with
50% reduction in biofilm metabolic activity (BEC50)
had the same value for both strains (3.9 lg/mL),
BEC80 value for C. parapsilosis was two times higher
(62.5 lg/mL), in comparison to the other tested strain.
Moreover, similar differences in minimum biofilm
fungicidal concentration (MBFC) for C. orthopsilosis
and C. parapsilosis indicated higher resistance of the
latter strain to (?)-usnic acid. In contrast, Kvasnick-
ova et al. (2015) demonstrated that (?)-usnic acid did
not exhibit any antibiofilm activity against C. parap-
silosis and C. krusei, up to 300 lg/mL.
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Antiviral activity
Only a few experiments have been carried out on the
antiviral activity of (?)-usnic acid. In the experiment
by Perry et al. (1999), (?)-usnic acid revealed
moderate activity against Herpes simplex type 1 and
Polio type 1 viruses, causing over 4 mm inhibition
zone at the concentration of 7.5 lg and 30 lg per disc,
respectively.
A possible explanation for the antiviral action of
(?)-usnic acid was suggested by Campanella et al.
(2002). Mouse 3T6 fibroblasts were transfected with
polyoma viruses, to check the ability of usnic acid to
influence viral DNA replication, and the cells were
incubated with or without (control) the tested com-
pound. The results indicate that the compound was
effective at the concentration of 5 lg/mL. The authors
showed that (?)-usnic acid strongly inhibited the
replication of viral RNA, isolated from previously
transfected cells.
Antiprotozoal activity
Some interesting results on antiprotozoal activity of
(?)-usnic acid have been published. Two authors have
studied the activity of (?)-usnic acid against a number
of Leishmania species. In the study by Fournet et al.
(1997), (?)-usnic acid was tested against
Table 3 Antifungal activity of usnic acid enantiomers
Fungal strain Activity References
(?)-usnic acid (-)-usnic acid
Aspergillus flavus MIC[ 250 lg/ml – Schmeda-Hirschmann et al. (2008)
Aspergillus fumigatus MIC[ 250 lg/ml – Schmeda-Hirschmann et al. (2008)
Aspergillus niger IZ 5 mm at 250 lg – Natić et al. (2004)
MIC[ 250 lg/ml – Schmeda-Hirschmann et al. (2008)
Candida albicans IZ 1 mm at 60 lg – Perry et al. (1999)
MIC 0.002 mM – Tay et al. (2004)
– MIC 0.15 lg Yilmaz et al. (2004)
– IZ 0–18 mm at 100 lg/ml Ivanova et al. (2004)
na – Paudel et al. (2010)
MIC[ 250 lg/ml – Schmeda-Hirschmann et al. (2008)
Candida glabrata MIC 0.002 mM – Tay et al. (2004)
– MIC 0.15 lg Yilmaz et al. (2004)
Candida orthopsilosis MFC 125 lg/ml – Pires et al. (2012)
Candida parapsilosis MFC 250 lg/ml – Pires et al. (2012)
Candida tropicalis MIC[ 250 lg/ml – Schmeda-Hirschmann et al. (2008)
Cryptococcus neoformans MIC[ 250 lg/ml – Schmeda-Hirschmann et al. (2008)
Microsporum gypseum MIC 250 lg/ml – Schmeda-Hirschmann et al. (2008)
Penicillium notatum – IZ 13 mm at 100 lg/ml Ivanova et al. (2004)
Phytophthora infestans na na Halama and Van Haluwin (2004)
Pythium ultimum na na Halama and Van Haluwin (2004)
Saccharomyces cerevisiae na – Correche et al. (1998)
MIC[ 250 lg/ml – Schmeda-Hirschmann et al. (2008)
Sporobolomyces salmonicolor – IZ 19 mm at100 lg/ml Ivanova et al. (2004)
Trichophyton rubrum MIC 100 lg/ml – Schmeda-Hirschmann et al. (2008)
Trichophyton mentagrophytes IZ 5 mm at 60 lg – Perry et al. (1999)
MIC 200 lg/ml – Schmeda-Hirschmann et al. (2008)
Ustilago maydis na na Halama and Van Haluwin (2004)
Verticillium albo-atrum – Growth inhibition at 100 lg/disc Proksa et al. (1996)
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promastigotes forms of Leishmania braziliensis, L.
amazonensis and L. donovani. Following a 48-hour
incubation with the tested compound, the total lysis of
the parasites was observed at the concentration of
25 lg/mL. Interestingly, the same effect was noticed
for control drug pentamidine at the same concentra-
tion, while ketoconazole, also used as a control, was
not active. In a similar in vitro study against three
Leishmania species, namely L. amazonensis, L.
brasiliensis and L. infantum, (?)-usnic acid caused a
100% lysis of the cells at the concentration of 100 lg/
mL (Schmeda-Hirschmann et al. 2008).
The antiparasitic potential of (?)-usnic acid against
Toxoplasmosa gondii was examined. The tested
compound inhibited the viability of the tachyzoite, in
a time and dose-dependent manner, and the effect for
the highest concentration used (4 9 10-6mol/L) was
comparable to the reference drug acetylospiramycin.
In addition, the compound also influenced the invasive
potential of the tachyzoites into cardiofibroblasts
in vitro, and the number of infected cells significantly
decreased. It is worth noting that the effect for (?)-
usnic acid was more profound than that observed for
control drug (Si et al. 2016).
The antiprotozoal activity of (?)-usnic acid was
also studied in vivo (Fournet et al. 1997; Si et al.
2016). The compound was administered to Leishma-
nia amazonensis infected BALB/c mice at the dose of
25 mg/kg body weight, by various routes: orally,
subcutaneously or by intralesional injections in the
infected footpad. The latter treatment with (?)-usnic
acid significantly decreased both lesion weight and the
parasite loads in the footpad by 43.34and 72.28%,
respectively, in comparison to untreated animals The
other routes of administration revealed rather an
increase in both parameters. It is important to note
that no toxic effects of (?)-usnic acid administration
were observed, except for a slight inflammation on the
footpad after the injections (Fournet et al. 1997).
In a similar study (?)-usnic acid at doses of 5, 10
and 20 mg/kg, and also (?)-usnic acid formulated in
liposomes at the dose of 10 mg/kg, were administered
intragastrically to Swiss Webster mice, infected with
tachyzoites of Toxoplasmosa gondii. The compound
with the highest tested concentration, and the com-
pound formulated in liposomes, significantly pro-
longed the survival time of mice infected with the
parasite, to 90 and 117%, respectively, and the latter
effect was better than this achieved with the control
drug acetylospiramycin. The tested compound also
caused the changes in membrane organelles of Tox-
oplasmosa tachyzoite, which influenced its virulence.
Unfortunately, no information concerning possible
toxic effects was provided by the authors (Si et al.
2016).
Insecticidal activity
Sahib et al. (2008) described the activity of (?)-usnic
acid against Xyleborus fornicatus, a beetle infecting
Camellia sinsensis cultivars in Sri Lanka. The growth
and development of the insects in various stages of
their life cycle were strongly affected by the addition
of the tested compound (at the concentration of 50, 75
and 100 ppm) to the artificial dietary media. In a
similar study (?)-usnic acid revealed insecticidal
activity against Glyptotermes dilatatus, a termite pest
of tea endemic to Sri Lanka. The starved insects were
administered 10 mg of the tested compound. This
caused a significant, 80% mortality of the termites
after 23 days of the exposure (Kathirgamanathar et al.
2005).
Phytotoxic activity
An inhibitory effect of (?)-usnic acid on photosyn-
thesis due to a decrease in carotenoids and chlorophyll
content in tomato plant cultivars and Quercus rotun-
difolia leaves has been reported (Latkowska et al.
2006; Bouaid and Vicente 1998). In a similar study
(?)-usnic acid, at a very low concentration range
1–2.5 lg/mL, inhibited the viability of the protoplasts
isolated from the leaves of Nicotiana tabacum, in a
dose-dependent manner. The growth of N. tabacum
cells in vitro was also inhibited, with the total
inhibitory effect seen at 5 lg/mL (Cardarelli et al.
1997). The tested compound also significantly inhib-
ited the growth of Scenedesmus quadricauda, a fresh
water algae genus, but the other tested genus Aste-
rochloris erici, a lichen photobiont, was much less
affected. The weaker phytotoxic effect observed in the
latter may result from its evolutionary adaptation to
the presence of usnic acid (Bačkor et al. 2010).
Immunomodulatory activity
The immunostimulatory potential of (?)-usnic acid on
peritoneal macrophages isolated from mice has been
123
536 Phytochem Rev (2019) 18:527–548
reported (Santos et al. 2004). At the concentration of
100 lg/mL, the compound stimulated hydrogen per-
oxide (65.68 nmol) and nitrogen oxide (83 lmol)
release from the tested cells, while the reference
substances used in the study (zymosan and LPS)
stimulated the release of hydrogen and nitrogen
reactive forms in 275.41 and 65 nmol, respectively.
However, no immunomodulatory effect of (?)-usnic
acid on the oxidative burst activity of whole blood
phagocytic cells and there was no release of reactive
oxygen radicals (Thadhani et al. 2015).
Cardiac function impairment
A recent study describes the influence of (?)-usnic
acid, complexed with hydroxypropylb-cyclodextrin
for better solubility, on myocardial contractility
in vitro. Isolated left atria of guinea pigs and rat
ventricular cardiomyocytes were used in the study.
The results indicate that (?)-usnic acid reduced atrial
contraction, observed as a decrease in Ca2? entry in
myocardial cells. In isolated cardiomyocytes, the
compound inhibited the L-type Ca2? current by
73.0% at 100 lM dose. In addition, (?)-usnic acid
caused an irreversible myocardial contracture, char-
acterized by a serious disturbance of the intracellular
Ca2? homeostasis. It is noteworthy that at the same
time cell membrane integrity was not affected (Men-
donça et al. 2017).
Anti-inflammatory activity
The anti-inflammatory activity of (?)-usnic acid was
studied both in vitro and in vivo. The results of the
conducted in vitro studies showed no inhibitory effect
of the compound on the platelet type12(S)-lipoxyge-
nase up to 100 lg/mL (Bucar et al. 2004) and only
weak inhibitory activity on leukotriene B4 synthesis in
polymorphonuclear leukocytes at IC50 42 ± 2.2 lM
(Kumar and Müller 1999a).
In an acute and chronic inflammation model,
dextrorotatory usnic acid, administered per os to rats
at 25, 50 and 100 mg/kg doses, caused a decrease in rat
paw edema and in the highest dose the effect was
comparable to the reference drug, ibuprofen. In a
chronic model (?)-usnic acid decreased the granula-
tion in a dose-dependent manner and the effect was
comparable to ibuprofen (Vijayakumar et al. 2000). In
a similar study (?)-usnic acid, administered orally to
mice in 30 and 100 mg/kg doses, revealed analgesic
activity, resulting in 50 and 40% decrease in animal
writhing, respectively, plus a long-term analgesic
effect seen in tail-pressure test. Regarding the effect
on normal body temperature and LPS-induced hyper-
thermia in mice, (?)-usnic acid showed a significant
effect only on the latter, causing the decrease in
temperature by 1 and 2.5 C for 100 and 300 mg/kg
doses, respectively, 4 h after the administration
(Okuyama et al. 1995).
An interesting study in the context of potential
toxicity concerns the comparison of the anti-inflam-
matory effect of (?)-usnic acid alone and encapsu-
lated in poly-e-caprolactone microsphere polymers.
Both compounds, administered subcutaneously to rats
in the dose of 25–50 mg/kg, significantly reduced paw
volume and decreased myeloperoxidase levels,
whereas only the encapsulated form of (?)-usnic acid
(50 mg/kg) significantly reduced the levels of inflam-
matory cytokines (IL-1b, TNF-a) and NO. It is
noteworthy that the (?)-usnic acid in microspheres
showed a lower acute toxicity than the free form. This
may have implications for further (?)-usnic acid
toxicity reduction (Barbosa et al. 2017).
Antimitotic activity
The antimitotic activity of (?)-usnic acid was exam-
ined using the Allium test. The compound inhibited the
growth and mitosis of the roots at the concentration of
0.0004% (Oświecimska et al. 1987).
Cytotoxic activity
The cytotoxic activity of (?)-usnic acid has been
extensively studied and the results, mainly expressed
as IC50 values, are summarized in Table 4. The
compound affected murine and human cancer cells
of different origin, with the activity described from
high to rather moderate, while showing a significantly
weaker effect on normal cells. This implicates the
selectivity of (?)-usnic acid. However, vast differ-
ences were observed between IC50 values obtained for
the same cancer line by different authors, as it can be
seen for HeLa or MCF7 cancer cell lines (Table 4),
and may be due to the different viability tests used.
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Table 4 Cytotoxic activity of usnic acid enantiomers
Cell line Activity References
(?)-usnic acid (-)-usnic acid
Animal origin
3LL
Lewis lung carcinoma
IC50 23 ± 6.6 lM IC50 35.1 ± 10.7 lM IC50
12.1 lg/ml
Bazin et al. (2008)
Bézivin et al. (2004)
B16-F10
Skin melanoma
LC50[ 250 lg/ml – Brandão et al. (2013)
L1210
Lymphocytic leukemia
IC50 26.4 ± 8.5 lM IC50 17.4 ± 1.4 lM Bazin et al. (2008)
– IC50 6 lg/ml Bézivin et al. (2004)
– 95% inhibition at
1.4 9 10-7 mol/mL (23 h)
Takai et al. (1979)
L-929
Fibroblasts
IC50 5.5 mg/ml – Ivanova et al. (2004)
MDCK
Madin-Darby canine kidney
IC50 133.04 ± 3.5 lM – Nguyen et al. (2014)
NIH-3T3
Fibroblasts
IC50[ 100 lM – Brisdelli et al. (2012)
LC50[ 250 lg/ml – Brandão et al. (2013)
IC50 164.2 ± 3.7 lM – Nguyen et al. (2014)
NS20Y
Neuroblastoma
– IC50 217.31 ± 3.51 (24 h),
52.18 ± 1.71 (48 h) lM
Koparal (2015)
P388
Leukemia
IC50 16 lg/ml – Perry et al. (1999)
Rat hepatocytes IC50 2 lM – Sonko et al. (2011)
RIE
Intestinal epithelial
IC50 126 ± 4.26 lM – Nguyen et al. (2014)
V79
Chinese hamster lung fibroblasts
Viability 60% at 25 lg/mL (24 h) Viability 90% at 25 lg/mL
(24 h)
Koparal et al. (2006)
Vero
Green monkey kidney
IC50[ 150 lM – Schinkovitz et al. (2014)
Wehi
Fibrosarcoma
EC50 15.8 lM – Dinçsoy and Cansaran Duman (2017)
Human origin
518A2
Melanoma
IC50 5.4 ± 0.3 lM – Draut et al. (2017)
A2780
Ovarian carcinoma
IC50 75.9 ± 2.0 lM – Bačkorová et al. (2011)
A431
Vulvar carcinoma
EC50 39 lM, 72 lM – Burlando et al. (2009)
A549
Lung cancer
Viability 85% at 25 lg/mL (24 h) Viability 100% at 25 lg/mL
(24 h)
Koparal et al. (2006)
IC50 65.3 ± 0.65 lM – Nguyen et al. (2014)
AGS
Gastric cancer
IC50 15.01 ± 0.52 lM – Nguyen et al. (2014)
BT-474
Breast cancer
IC50 15.1 lM – Ebrahim et al. (2017)
CaCo2
Colorectal adenocarcinoma
EC50 7.05 lM – Dinçsoy and Cansaran Duman (2017)
Capan-2
Pancreatic cancer
IC50 5.3 lg/mL IC50 5.0 lg/mL Einarsdottir et al. (2010)
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Table 4 continued
Cell line Activity References
(?)-usnic acid (-)-usnic acid
CWR22Rv1
Prostate cancer
IC50 24.1 ± 0.63 lM – Nguyen et al. (2014)
DLD-1
Colon carcinoma
IC50 19.3 ± 5.9 lM – Draut et al. (2017)
Du145
Prostate cancer
IC50 57.4 ± 2.1 lM IC50 45.9 ± 7.0 lM IC50
15.8 lg/ml
Bazin et al. (2008)
Bézivin et al. (2004)
Ea.Hy 926
Endothelial cells
IC50[ 50 lM – Draut et al. (2017)
H1299
Non-small lung carcinoma
IC50 22.3 lM – Mayer et al. (2005)
HaCaT
Keratinocytes
IC50 2.1 ± 0.7 lM – Kumar and Müller (1999b)
EC50 35 lM, 76 lM – Burlando et al. (2009)
IC50 185.7 ± 4.8 lM – Nguyen et al. (2014)
HCT-116 p53-/-
Colon carcinoma p53 null
IC50 143.1 ± 11.3 lM – Bačkorová et al. (2011)
HCT-116 p53?/?
Colon carcinoma wild type p53
IC50 157.2 ± 4.0 lM – Bačkorová et al. (2011)
HCT-116
Colon carcinoma
IC50 17.7 ± 5.4 lM – Brisdelli et al. (2012)
HEC-50
Endometrial adenocarcinoma
70% inhibition at 50 lg/ml (46 h) – Cardarelli et al. (1997)
HEK293T
Embryonic kidney
IC50 85.3 ± 0.75 lM – Nguyen et al. (2014)
HeLa
Cervix adenocarcinoma
IC50 14.9 lM – Natić et al. (2004)
IC50 178.3 ± 9.7 lM – Bačkorová et al. (2011)
IC50[ 10 lM – Schinkovitz et al. (2014)
IC50 23.7 ± 2.5 lM – Brisdelli et al. (2012)
IC50 5.1 mg/ml – Ivanova et al. (2004)
Hep2C
Cervix carcinoma
EC50 21.8 lM – Dinçsoy and Cansaran Duman (2017)
HepG2
Hepatoblastoma
– IC50 160.6 ± 4.38 (24 h),
50.24 ± 1.23 (48 h) lM
Koparal (2015)
LC50 30 lM – Sahu et al. (2011)
EC50 15.04 lM – Dinçsoy and Cansaran Duman (2017)
HL-60
Promyelotic leukemia
IC50 14.3 ± 0.1 lM – Toledo Marante et al. (2003)
IC50 48.5 ± 9.1 lM – Bačkorová et al. (2011)
IC50 5.4 (24 h), 1.7 (48 h) lM – Schinkovitz et al. (2014)
HT-29
Colon cancer
IC50 99.7 ± 8.4 lM – Bačkorová et al. (2011)
IC50 95.2 ± 0.85 lM – Nguyen et al. (2014)
HUVEC
Umbilical vein endothelial cells
– IC50 427.9 ± 1.15 (24 h),
71.5 ± 0.19 (48 h) lM
Koparal (2015)
Ishikawa
Endometrial carcinoma
90% inhibition at 5 lg/ml (46 h) – Cardarelli et al. (1997)
Jurkat
Lymphocyte leukemia
IC50 76.3 ± 8.2 lM – Bačkorová et al. (2011)
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Table 4 continued
Cell line Activity References
(?)-usnic acid (-)-usnic acid
K-562
Chronic myelogenous leukemia
IC5052.8 ± 8.7 lM IC50 21.8 ± 3.8 lM Bazin et al. (2008)
– IC50 8.2 lg/ml Bézivin et al. (2004)
90% inhibition at 50 lg/ml (46 h) – Cardarelli et al. (1997)
IC50 3.0 mg/ml – Ivanova et al. (2004)
KB-V1/Vbl
Cervix carcinoma
IC50 9.6 ± 0.1 lM – Draut et al. (2017)
MCF7
Breast adenocarcinoma
IC50 18.9 lM – Mayer et al. (2005)
IC50 105.4 ± 16 lM IC50 51.7 ± 7.3 lM Ebrahim et al. (2017)
IC50 94.6 ± 7.9 lM IC50 17.8 lg/ml Bazin et al. (2008)
Bézivin et al. (2004)
IC50 11.2 ± 1.25 lM – Bačkorová et al. (2011)
IC50 75.7 ± 3.4 lM – Brisdelli et al. (2012)
IC50 16.4 ± 2.5 lM – Draut et al. (2017)
IC50 11.2 lM – Ebrahim et al. (2017)
IC50 34.12 ± 1.25 lM Zuo et al. (2015)
MDA-MB-231
Breast cancer
IC50 22.3 lM – Mayer et al. (2005)
IC50 13.1 ± 0.76 lM – Ebrahim et al. (2017)
IC50 38.41 ± 1.64 lM – Zuo et al. (2015)
MDA-MB-468
Breast cancer
IC50 13.7 lM – Ebrahim et al. (2017)
MM98
Sarcomatous mesothieloma
EC50 23 lM – Burlando et al. (2009)
Panc-1
Pancreatic carcinoma
EC50 4.3 lg/ml – Kristmundsdottir et al. (2005)
IC50 10.8 ± 1.2 lM – Draut et al. (2017)
PC-3
Prostate cancer
EC50 8.2 lg/ml – Kristmundsdottir et al. (2005)
RD
Rhabdomyelosarcoma
EC50 22.9 lM – Dinçsoy and Cansaran Duman (2017)
SK-BR-3
Breast adenocarcinoma
IC50 199.2 ± 18.8 lM – Bačkorová et al. (2011)
IC50 14.4 lM – Ebrahim et al. (2017)
IC50 48.07 ± 1.52 lM – Zuo et al. (2015)
SH-SY5Y
Neuroblastoma
Viability 41.9% at 2 lg/mL (24 h) – Rabelo et al. (2012)
T-47D
Breast cancer
EC50 2.9 lg/ml – Kristmundsdottir et al. (2005)
IC50 4.2 lg/mL IC50 4.0 lg/Ml Einarsdottir et al. (2010)
IC50 15.9 lM – Ebrahim et al. (2017)
UACC-62
Melanoma
LC50 184 lg/ml – Brandão et al. (2013)
U251 glioblastoma IC5019.5 ± 1.6 lM IC5019.7 ± 4.6 lM Bazin et al. (2008)
– IC50 6.8 lg/ml Bézivin et al. (2004)
U87MG
Glioblastoma
IC50 41.55 mg/l – Emsen et al. (2018)
U937
Monoblastic leukemia
IC50 14.3 ± 0.1 lM – Toledo Marante et al. (2003)
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Anticancer properties
Despite a great number of in vitro cytotoxicity studies
of (?)-usnic acid, the data on its in vivo antitumor
potential is scarce.
Intraperitoneal administration of (?)-usnic acid to
sarcoma 180-bearing mice at a dose of 15 mg/kg, in its
free and PLGA-encapsulated form resulted in a 63%
inhibition of tumor growth for the latter. In the case of
the free compound, there was only 42% inhibition. It is
worth noting that both tested forms of (?)-usnic acid
caused no histopathological changes in liver, spleen or
kidneys of the animals (Ribeiro-Costa et al. 2004). In a
further experiment, under the same experimental
conditions, the results were similar, with an inhibition
of tumor growth of 43.3 and 69.7% for free and
encapsulated (?)-usnic acid, respectively. Moreover,
the decrease in hepatotoxicity for the latter was
observed, with less hepatocytes vacuolization and a
decrease in the levels of liver enzymes (da Silva
Santos et al. 2006).
An interesting experiment was recently described
by Su et al. (2017), who examined the effect-
enhancing and toxicity-reducing activity of (?)-usnic
acid on hepatoma H22-bearing mice treated with
bleomycin. Usnic acid (25, 50 and 100 mg/kg, p.o.)
administered together with bleomycin (15 mg/kg, i.p.)
was significantly more effective than the cytostatic
alone in inhibiting tumor growth, and also in apoptosis
inducement in cancer cells. Moreover, (?)-usnic acid
decreased some of the side effects of bleomycin, such
as lung-tissue damage or excessive production of
extracellular matrix, oxygen radical and inflammatory
cytokines.
Antioxidant properties
No antioxidant effect of (?)-usnic acid in DPPH test
up to 0.8 mM was proved (Kumar and Müller 1999a;
Brisdelli et al. 2012). Moreover, the compound at the
concentration up to 250 lM was not able to protect rat
brain homogenate tissue with oxidative stress induced
with H2O2/Fe
2? (Toledo Marante et al. 2003). Also,
no prooxidant properties of (?)-usnic acid on lipids in
model membranes were found (Kumar and Müller
1999a). In an interesting study by Suwalsky et al.
(2015), (?)-usnic acid did neutralize the oxidative
impact of hypochlorous acid on human erythrocytes
cell membranes and also on their molecular models, at
the concentration range 2–17.5 lM.
Antiangiogenic activity
The antiangiogenic potential of (?)-usnic acid was
examined both in vitro, using the human umbilical
vein endothelial cell (HUVEC) tube formation assay,
and in vivo, using the zebrafish embryos or chick
embryo chorioallantoic membrane (CAM) assay and
the mouse corneal micropocket model. The results
from the in vitro model indicate that (?)-usnic acid
inhibited about 50% of tube formation at a concentra-
tion of 20 lM, after 8–12 h of incubation, as com-
pared to the untreated cells (Song et al. 2012). In the
in vivo study, the formation of new blood vessels was
blocked by (?)-usnic acid (1 lg/disc) in the CAM
model, and in the VEGF-induced angiogenesis in the
mouse cornea, there was marked inhibition. It is
significant that no adverse effects such as eye inflam-
mation or corneal edema were observed during the
treatment. Moreover, the authors also described the
influence of the tested compound on breast tumor
angiogenesis in the mouse xenograft model and they
observed that the mean integrated optical density of
tumor blood vessels was obviously less in the treated
(50 mg UA/kg/day intraperitoneally, 7 days), in com-
parison to the untreated animals (Song et al. 2012).
The study on zebrafish embryos also revealed signif-
icant antiangiogenic effects, such as the reduction of
intersegmental vessels, dorsal longitudinal anasto-
motic vessels, subintestinal veins and secondary
sprouts. Side effects of pericardial edema and the
impairment of blood flow were noticed, together with
a curvature of the spine (Draut et al. 2017).
Genotoxic and mutagenic properties
Studies by Polat et al. (2016), using the micronucleus
assay, on the right-handed enantiomer of usnic acid
indicate that the compound is not genotoxic to human
lymphocytes, instead it can have a protective effect in
concentrations up to 200 lg/mL due to its antioxidant
properties. Both in vitro and in vivo studies of the
genotoxic potential of (?)-usnic acid, using the
hamster lung fibroblasts V79 and Swiss mice model,
were also described. Results obtained in the in vitro
micronucleus assay indicate that the compound was
not genotoxic, but it did cause DNA damage. This was
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observed in the comet assay at the doses of 60 and
120 lg/mL. Moreover, the addition of (?)-usnic acid
significantly reduced the frequency of micronuclei and
DNA damage, induced by the administration of
genotoxin, methyl methanesulfonate (MMS). No
genotoxic effects were observed in Swiss mice given
up to 200 mg/kg b.w. of MMS; rather a protective,
antigenotoxic effect was observed following (?)-
usnic acid administration (Leandro et al. 2013). Mayer
et al. (2005) reported on the cytotoxic, but not the
genotoxic effect of (?)-usnic acid on breast cancer
MCF7 cells, up to 20 lM. No phosphorylation of p53
at Ser15, a signal transmission after DNA damage,
was observed in the cells. On the other hand, (?)-usnic
acid, at doses of up to 20 mM caused mutagenic and
carcinogenic changes in the somatic cells of Droso-
phila melanogaster larvae (Machado et al. 2016).
Toxicity
In a study by Abo-Khatwa et al. (2015), (?)-usnic acid
at the dose of 80–280 mg/kg was administered
subcutaneously to mice to determine its potential
toxicity. The median lethal dose of the compound was
180 mg/kg and the toxic symptoms included: long
chalasia, ponopalmosis or spastic paralysis. These
symptoms were most evident 2–5 h following treat-
ment. In addition, the uncoupling of oxidative phos-
phorylation in the mitochondria isolated from these
mice were observed. In another study (Joseph et al.
2009), the effect of (?)-usnic acid, administered per os
to mice at 60–600 ppm, resulted in a 4-fold effect on
the expression of several genes associated with the
complexes I to IV of the mitochondrial electron
transport chain. The genes involved in the Krebs cycle,
fatty acid oxidation, and membrane transport were
also over-expressed. The authors suggest that this may
be a specific compensatory response to (?)-usnic acid,
which caused an uncoupling of the proton gradient
which maintains the mitochondrial membrane. The
toxicity of (?)-usnic acid was also studied by Dailey
et al. (2008), who administered the compound per os to
domestic sheep. The toxic symptoms included:
lethargy, anorexia and abdominal discomfort, and
the median toxic dose was estimated between 485 and
647 mg/kg/day for 7 days.
Hepatotoxicity
Numerous studies describe toxic impact of usnic acid
on liver function both in vitro and in vivo, including
severe hepatotoxicity following intake of some dietary
supplements for weight loss which contained this
compound. This problem was discussed in detail in
two recent review papers by Guo et al. (2008) and
Araújo et al. (2015). It should be stressed that only
some of these studies indicated the specific rotation of
the tested usnic acid to be the (?)-enantiomer. In the
abovementioned study on domestic sheep (see the
section on ‘Toxicity’’) the levels of creatine kinase,
aspartate aminotransferase and lactate dehydrogenase
were considerably elevated in the serum of the animals
treated with (?)-usnic acid (Dailey et al. 2008).
Similar increases in serum alanine aminotransferase
and total bilirubin levels in Wistar rats treated with
100, 200 and 240 mg/kg of (?)-usnic acid, together
with hydropic degeneration of hepatocytes was
described by Lu et al. (2011). However, in the
aforementioned study of Silva Santos et al. (see the
section on ‘‘Anticancer properties’’) the hepatotoxic
effect of (?)-usnic acid was significantly decreased
when the compound was used in the nanoencapsulated
form. Moreover, the dose of (?)-usnic acid, which was
effective for tumor inhibition in the treated mice (da
Silva Santos et al. 2006), was ten to 30-fold lower than
that used in the toxicity studies of Lu et al. and Dailey
et al., respectively. The suggested mechanism of the
hepatotoxicity of usnic acid may be connected with its
impact on the loss of cell membrane integrity and
disruption of mitochondrial functions (Pramyothin
et al. 2004), however the details of the process have
not yet been defined. In our own studies on human, rat
and mouse microsomes we have shown the idiosyn-
cratic character of hepatotoxicity of usnic acid. This is
due to the generation of its reactive metabolites, which
form adducts with glutathione. Moreover, our results
of in silico studies suggest that the hepatotoxicity can
be reduced by designing usnic acid derivatives lacking
ortho-methyl phenols (Piska et al. 2018).
Activity reported solely for (-)-usnic acid
The biological and pharmacological properties of (-)-
usnic acid are described less often in experimental
papers in comparison to its right-handed enantiomer
and cover only selected areas of activities.
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Antibacterial and antifungal activity
The antibacterial and antifungal activities of left-
handed usnic acid are summarized in Tables 2 and 3.
No information is available on the possible inhibitory
effect on bacterial or fungal biofilm formation of (-)-
usnic acid.
Antimitotic activity
The antimitotic activity of (-)-usnic acid was exam-
ined using the Allium test. This compound inhibited
the growth and mitosis of roots at concentration of
0.25 and 2.5 lg/mL (Huovinen and Lampero 1989).
Cytotoxic activity
Only a few studies describe the influence of left-
handed enantiomer on cancer cells in vitro and the
results are summarized in Table 4. The cytotoxic
activity may be regarded as rather high, although
further studies are needed on other types of murine and
human cancer cell lines of different origin to obtain
more clear evidence. Moreover, the information
available on the potential selectivity of (-)-usnic acid
is scarce. Only two experiments have been conducted
to measure its activity against normal cells, with rather
moderate toxicity.
Anticancer properties
Two studies, dating back to 1970s, concern anticancer
properties of (-)-usnic acid. In the earliest experiment
(-)-usnic acid, administered at doses of 20–200 mg/
kg, caused a 35–52% increase in survival of mice with
Lewis lung carcinoma, in comparison to the untreated
group (Kupchan and Kopperman 1975). Further
experiment by Takai et al. (1979) indicated a moderate
antitumor effect of (-)-usnic acid. The compound,
administered intraperitoneally to mice with P388
leukemia in a dose of 100 mg/kg, extended the
survival time of the animals up to 41%, as compared
to the controls. In both reports no information
concerning the potential toxicity of the compound
was provided.
Photoprotective activity
In one study (-)-usnic acid showed a protective effect
on UVB irradiated human keratinocytes at a concen-
tration of 100 lM (Varol et al. 2015).
Antiangiogenic activity
In a study by Koparal (2015), (-)-usnic acid demon-
strated antiangiogenic properties by inhibiting tube
formation in a time and dose dependent manner, with
IC50 427.9 and 71.5 lM after 24 and 48 h of
incubation, respectively.
Activity reported for mixtures of both enantiomers
In the time scope covered by this review only two
reports have been published on the activity of usnic
acid racemic or scalemic mixtures. In one of them the
effects of racemate and the both single enantiomers
were compared under the same experimental condi-
tions. The antibacterial activity of racemic usnic acid
against Mycobacterium tuberculosis did not differ
from either single enantiomer. The activity of racemic
usnic acid against Staphylococcus aureus was identi-
cal to this caused by (?)-usnic acid but weaker than
that of the left-handed enantiomer (Shibata et al.
1948). One recent study described the antioxidant
properties of usnic acid isolated from Vulpicida
pinastri, which occurred as a mixture of (?)- and
(-)-isomers in 35/65 ratio. The mixture of both
isomers revealed moderate antioxidant activity in the
superoxide radical scavenging NBT test in comparison
to ascorbic acid used as a positive control, with IC50 24
and 3 lg/mL, respectively, while no activity in DPPH
test was observed, with IC50 [ 500 lg/mL (Legouin
et al. 2017). The same authors also described the
photoprotective potential of the mixture of enan-
tiomers. The tested substance revealed to be a good
UVB filter, and the activity was comparable to OMC
(octylmethoxycinnamate), used as a positive control.
Moreover, the compound was photostable after UVA
irradiation, retaining its protective properties. The
authors also measured the phototoxic potential of
usnic acid on irradiated keratinocytes, reporting the
calculated photo-irritancy factor (PIF) as 0.7, while
the threshold value is established at 5 (Legouin et al.
2017).
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Challenges and future perspectives
Considering the perspectives for further usnic acid
studies, two major points should be emphasized: the
problem of the identity and purity of both enantiomers
and also the comparison of their activity. Bioactivity
screening of usnic acid should be preceded by careful
characterization of its enantiomeric purity. Formerly
recognized lichen taxa producing certain usnic acid
isomer should be subjected to a more thorough
examination (see the case of Cladonia stellaris in the
‘‘Distribution and identification of usnic acid enan-
tiomers’’ section). It should be also noted that
geographical origin of the lichen, or genetic variety
of the fungal component, may also induce qualitative
and quantitative differentiation between individual
samples of the same species, including the production
of (?)- or (-)-isomer of usnic acid. Thus, it is
extremely important not only to correctly identify the
lichen species to be studied, but also to determine the
specific rotation of usnic acid enantiomers or the ratio
of the mixture.
Although a great number of reports have been
published on the biological and pharmacological
activities of individual usnic acid enantiomers, a vast
majority of them concern the right-handed enantiomer
while (-)-usnic acid seems to be definitely less
examined. One of the reasons may be the fact that
the sole commercially available usnic acid is the right-
handed enantiomer. The increase of the studies on
both usnic acid enantiomers under the same experi-
mental conditions is crucial for drawing any final
conclusions on the superiority of any of them. The
results of all the studies cited in this paper do not
provide a clear answer as to whether one of the two
enantiomers is more beneficial over the other. Signif-
icant and vast differences between (?)- and (-)-usnic
acid were observed in only a few reports on antiviral
(Sokolov et al. 2012; Yamamoto et al. 1995), insec-
ticidal (Emmerich et al. 1993) and phytotoxic activity
(Romagni et al. 2000). The predominance of neither
enantiomer can be proposed on the basis of their
results. Moreover, almost no information exists on the
possible reasons for the differences observed between
the activities of both enantiomers. The aforementioned
superiority of (-)-usnic acid over the totally inactive
(?)-usnic in terms of phytotoxic activity was con-
nected with blocking of some plant enzymes by the
former (Romagni et al. 2000). This may have be the
result of some differences in the steric fitting of the
enantiomers to the active site of the enzyme. Similar
explanation might be proposed concerning differences
in the cytotoxic impact of both usnic acid enantiomers.
Cancer cells of different origin are phenotypically
heterogenic and expose varied receptors on their
surface, to which the enantiomers may connect and
trigger different effect, depending on their steric
configuration. Since the data comparing the activity
of both usnic acid enantiomers under the same
experimental conditions are scarce, no further specu-
lative explanations can be drawn. Moreover, as no
information exists on the steric structure–activity
relationship of both usnic acid enantiomers, the
problem remains an important challenge for further
studies. Another promising direction for future usnic
acid research should be toward the biological and
pharmacological activities of its racemic mixtures.
Additionally, the efforts should be made to explain the
mechanism of hepatotoxicity of usnic acid and to
develop the formulations or the derivatives which will
provide the increase in its safety.
Conclusions
Usnic acid is a compound of unique structure, existing
in the form of two enantiomers, with interesting
bioactivity. Antimicrobial, cytotoxic or anti-inflam-
matory properties of usnic acid enantiomers seem to
be the most promising, but the predominance of any of
the enantiomers is still an open question. In the light of
all the challenges mentioned above, accurate, well-
planned future experiments on both usnic acid enan-
tiomers need to be conducted. Their results should
enable one to determine if any of the two usnic acid
enantiomers is more active than the other and can be
preselected as a lead compound for future studies.
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